• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (GFO) LUTONIX 035 DRUG COATED BALLOON PTA CATHETER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (GFO) LUTONIX 035 DRUG COATED BALLOON PTA CATHETER Back to Search Results
Model Number 9004
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code Reocclusion (1985)
Date of Event 04/06/2017
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Analysis: the sample was not returned to the user facility; therefore, device evaluation is unable to be performed.A lot history review revealed (b)(4) additional reocclusion complaint associated with this lot.A review of the device history record (dhr) shows the lot was manufactured to specification.Conclusion: the actual sample was not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was possibly related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of a reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided will all relevant information.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
 
Event or Problem Description
It was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the distal superficial femoral artery (sfa).Approximately 6 months after the index procedure, the patient¿s distal sfa vessel was reportedly reoccluded.A revascularization was performed involving a stent placement and the hcp deemed it was successful.The investigator assessed the event was possibly related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.
 
Event or Problem Description
It was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the distal superficial femoral artery (sfa).Approximately 6 months after the index procedure, the patient¿s distal sfa vessel was reportedly reoccluded.A revascularization was performed involving a stent placement and the hcp deemed it was successful.The investigator assessed the event was not related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.
 
Additional Manufacturer Narrative
Additional information: the event description sentence was changed from " the investigator assessed the event was possibly related to the study device or procedure." to "the investigator assessed the event was not related to the study device or procedure." eval code & desc - results added 213 corrected information: the udi no.Was changed from "(b)(4)" to "(b)(4)." eval code & desc method changed from 3317 and 3263 to 4115,3331,4110.Eval code & desc - conclusion changed from 92 to 4310.The sample was not returned to the user facility; therefore, device evaluation is unable to be performed.A lot history review revealed 1 additional reocclusion complaint associated with this lot.A review of the device history record (dhr) shows the lot was manufactured to specification.Conclusion: the actual sample was not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of a reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided will all relevant information.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LUTONIX 035 DRUG COATED BALLOON PTA CATHETER
Common Device Name
DRUG COATED BALLOON PTA CATHETER
Manufacturer (Section D)
C.R. BARD, INC. (GFO)
289 bay road
queensbury NY 12804
MDR Report Key6604193
Report Number3006513822-2017-00110
Device Sequence Number19125248
Product Code ONU
UDI-Device Identifier00801741088742
UDI-Public(01)00801741088742(17)170831(10)GFZH2964
Combination Product (Y/N)N
Initial Reporter CountryCH
PMA/510(K) Number
P130024
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source foreign,health professional,o
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 11/20/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date08/31/2017
Device Model Number9004
Device Catalogue Number9050613400150
Device Lot NumberGFZH2964
Was Device Available for Evaluation? No
Event Location Hospital
Initial Date Received by Manufacturer Not provided
Supplement Date Received by Manufacturer11/12/2018
Initial Report FDA Received Date06/01/2017
Supplement Report FDA Received Date11/20/2018
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age66 YR
Patient Weight72
-
-